2026 BD opportunity scan for GlaxoSmithKline KK: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Glaukos Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Genmab A/S: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Generium ZAO: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for GE Healthcare Technologies, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach ratio

2026 BD opportunity scan for GC Biopharma Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Galderma SA (Switzerland): pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for FutureGen Biopharmaceutical (Beijing) Co., Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and

2026 BD opportunity scan for Fujian Haixi New Drug Creation Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outrea

2026 BD opportunity scan for Fujian Cosunter Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outrea

2026 BD opportunity scan for FluoGuide A/S: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Eyebiotech Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.